PMCB vs. SNTI, APTO, TVGN, EVAX, ZIVO, AIM, COEP, CHRO, GENE, and BCLI
Should you be buying PharmaCyte Biotech stock or one of its competitors? The main competitors of PharmaCyte Biotech include Senti Biosciences (SNTI), Aptose Biosciences (APTO), Tevogen Bio (TVGN), Evaxion Biotech A/S (EVAX), ZIVO Bioscience (ZIVO), AIM ImmunoTech (AIM), Coeptis Therapeutics (COEP), Chromocell Therapeutics (CHRO), Genetic Technologies (GENE), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "biological products, except diagnostic" industry.
Senti Biosciences (NASDAQ:SNTI) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
PharmaCyte Biotech has lower revenue, but higher earnings than Senti Biosciences. PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
PharmaCyte Biotech has a net margin of 0.00% compared to PharmaCyte Biotech's net margin of -2,692.82%. Senti Biosciences' return on equity of -9.69% beat PharmaCyte Biotech's return on equity.
25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are owned by institutional investors. 12.5% of Senti Biosciences shares are owned by company insiders. Comparatively, 1.0% of PharmaCyte Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Senti Biosciences currently has a consensus price target of $6.00, indicating a potential upside of 1,526.46%. Given PharmaCyte Biotech's higher possible upside, analysts plainly believe Senti Biosciences is more favorable than PharmaCyte Biotech.
Senti Biosciences has a beta of 2.88, indicating that its share price is 188% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500.
In the previous week, Senti Biosciences had 5 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 8 mentions for Senti Biosciences and 3 mentions for PharmaCyte Biotech. Senti Biosciences' average media sentiment score of 1.19 beat PharmaCyte Biotech's score of -0.11 indicating that PharmaCyte Biotech is being referred to more favorably in the news media.
Senti Biosciences received 3 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users.
Summary
Senti Biosciences beats PharmaCyte Biotech on 8 of the 15 factors compared between the two stocks.
Get PharmaCyte Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PharmaCyte Biotech Competitors List
Related Companies and Tools
